Arcturus Therapeutics (ARCT)
NASDAQ:ARCT
Want to see ARCT full AI Analyst Report?
ARCT Stock Chart & Stats
$8.85
-$1.70(-8.19%)
At close: 4:00 PM EST
$8.85
-$1.70(-8.19%)
Day’s Range― - ―
52-Week Range$5.85 - $24.17
Previous CloseN/A
Volume109.32K
Average Volume (3M)829.62K
Market Cap
$198.11M
Enterprise Value$33.42M
Total Cash (Recent Filing)$211.38M
Total Debt (Recent Filing)$23.99M
Price to Earnings (P/E)―
Beta2.35
Next Earnings
Aug 10, 2026Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.83
Shares Outstanding28,423,069
10 Day Avg. Volume934,920
30 Day Avg. Volume829,622
Financial Highlights & Ratios
PEG Ratio0.13
Price to Book (P/B)0.78
Price to Sales (P/S)2.50
P/FCF Ratio-2.26
Enterprise Value/Market Cap0.17
Enterprise Value/Revenue0.74
Enterprise Value/Gross Profit0.81
Enterprise Value/Ebitda-0.49
Forecast
1Y Price Target
$18.00Price Target Upside103.39% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
EPS Forecast (FY)-4.02
Revenue Forecast (FY)$17.05M
Bulls Say, Bears Say
Bulls Say
Proprietary LUNAR Delivery & Repeat Inhaled DosingArcturus's LUNAR particle chemistry and mRNA purification enabling tolerable multi-week inhaled dosing is a durable platform advantage for respiratory indications. This technological differentiation supports feasibility of at-home dosing, improves development prospects versus rivals, and strengthens long-term commercial potential in inhaled mRNA therapies.
Cash Runway Through Mid‑2028A stated cash runway beyond Q2 2028 provides multi‑quarter financing visibility to execute pivotal trials and regulatory meetings without immediate capital raises. This reduces near‑term dilution risk, gives management time to de‑risk programs, and supports sustained investment in clinical milestones over the next 2+ years.
Strategic Partnerships And Manufacturing SupportCommercial partner manufacturing (Meiji) and collaboration agreements de‑risk scale‑up and market access, moving manufacturing and commercial execution off Arcturus's core balance sheet. Partnerships can generate milestone/licensing cash, validate the platform commercially, and allow R&D focus on pipeline advancement rather than large capex.
Bears Say
Material Revenue ContractionA sustained ~37% TTM revenue decline indicates structural loss of prior pandemic vaccine revenue and uneven partner payments. Reduced recurring revenue weakens the firm's ability to cover fixed operating costs, increases reliance on milestone timing, and makes multi‑year planning and internal funding of trials more dependent on external financing or partner milestones.
Negative Operating And Free Cash FlowPersistently negative operating and free cash flow signal ongoing burn that will need funding if milestones slip. Even with current runway, negative cash generation reduces financial flexibility, raises the risk of dilutive capital raises if clinical timelines or partner payments are delayed, and constrains long‑term self‑funding of programs.
Modality And Clinical/regulatory Risk In Inhaled MRNACompetitor trial discontinuation and a small, open‑label CF study increase regulatory and safety scrutiny for inhaled mRNA. Modality risk can lead to heightened endpoint expectations, larger or controlled trials, or delayed approvals—raising development cost, slowing timelines, and challenging the predictability of regulatory success.
Arcturus Therapeutics News
ARCT FAQ
What was Arcturus Therapeutics’s price range in the past 12 months?
Arcturus Therapeutics lowest stock price was $5.85 and its highest was $24.17 in the past 12 months.
What is Arcturus Therapeutics’s market cap?
Arcturus Therapeutics’s market cap is $198.11M.
When is Arcturus Therapeutics’s upcoming earnings report date?
Arcturus Therapeutics’s upcoming earnings report date is Aug 10, 2026 which is in 55 days.
How were Arcturus Therapeutics’s earnings last quarter?
Arcturus Therapeutics released its earnings results on May 07, 2026. The company reported -$0.95 earnings per share for the quarter, beating the consensus estimate of -$1.01 by $0.06.
Is Arcturus Therapeutics overvalued?
According to Wall Street analysts Arcturus Therapeutics’s price is currently Undervalued.
Does Arcturus Therapeutics pay dividends?
Arcturus Therapeutics pays a Notavailable dividend of $0.06 which represents an annual dividend yield of N/A. See more information on Arcturus Therapeutics dividends here
What is Arcturus Therapeutics’s EPS estimate?
Arcturus Therapeutics’s EPS estimate is -1.
How many shares outstanding does Arcturus Therapeutics have?
Arcturus Therapeutics has 28,423,069 shares outstanding.
What happened to Arcturus Therapeutics’s price movement after its last earnings report?
Arcturus Therapeutics reported an EPS of -$0.95 in its last earnings report, beating expectations of -$1.01. Following the earnings report the stock price went up 3.596%.
Which hedge fund is a major shareholder of Arcturus Therapeutics?
Currently, no hedge funds are holding shares in ARCT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Arcturus Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$18.00 (103.39% Upside)
$18.00 (103.39% Upside)
Hedge Fund Trend
Increased
By 91.8K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.9%
Last 30 Days ▼ 4.9%
Last 30 Days ▼ 4.9%
Technicals
SMA
Positive
20 days / 200 days
Momentum
0.29%
12-Months-Change
Fundamentals
Return on Equity
-36.55%
Trailing 12-Months
Asset Growth
-26.03%
Trailing 12-Months
Company Description
Arcturus Therapeutics
Arcturus Therapeutics Holdings Inc. is a biotechnology company focused on RNA-based medicines, developing a pipeline of vaccines for infectious diseases alongside treatments for rare liver and respiratory conditions across the United States. Its notable development programs encompass LUNAR-OTC, designed for ornithine transcarbamylase (OTC) deficiency, and LUNAR-CF, targeting cystic fibrosis lung disease caused by specific CFTR gene mutations. The company also advances vaccine initiatives such as LUNAR-COV19 and LUNAR-FLU. Arcturus has cultivated a range of strategic collaborations, including partnerships with Vinbiocare Biotechnology Joint Stock Company for manufacturing COVID-19 vaccines; Janssen Pharmaceuticals, Inc., to create nucleic acid-based therapies for hepatitis B virus; Ultragenyx Pharmaceutical, Inc., for developing mRNA therapeutics aimed at rare disease targets; CureVac AG, to progress mRNA therapeutic and vaccine candidates across various indications; the Singapore Economic Development Board and Duke-NUS Medical School, specifically for the LUNAR-COV19 vaccine; and Millennium Pharmaceuticals, Inc., focused on discovering siRNA medicines for non-alcoholic steatohepatitis (NASH). Founded in 2013, Arcturus Therapeutics maintains its corporate headquarters in San Diego, California.
ARCT Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized meaningful clinical and regulatory progress — notably initiation of a 12‑week ARCT‑032 Phase II with tolerable repeat inhaled dosing and FDA clarity on ARCT‑810 pediatric path — supported by a strengthened leadership team and a cash runway through mid‑2028. Offsetting these positives were a material year‑over‑year revenue decline ($27.3M), a quarter‑over‑quarter cash decrease (~$19.4M, 8.3%), program‑specific manufacturing cost increases, and uncertainties tied to a small open‑label CF study and broader modality risk. On balance, the advancement of key programs and regulatory alignment outweigh the financial and operational headwinds in the near term.View all ARCT earnings summariesARCT Stock 12 Month Forecast
Average Price Target
$18.00
▲(103.39% Upside)
Technical Analysis
Rigel
―
Arvinas Holding Company
―
Compass Therapeutics
―
Olema Pharmaceuticals
―
Erasca
―
Ownership Overview
7.52% Insiders
24.37% Mutual Funds
31.73% Other Institutional Investors
16.15% Public Companies and
Individual Investors